FDA to Decide on New Duchenne Muscular Dystrophy Therapies from Dyne and Novartis by Early 2027

The regulatory landscape for Duchenne muscular dystrophy (DMD) is shifting toward a new generation of high-potency therapies, offering hope to patients who were previously ineligible for earlier treatments or found their clinical benefits limited. As of September 2026, two major pharmaceutical players, Dyne Therapeutics and Novartis, have moved into the final stages of FDA review for drugs that produce significantly higher levels of the muscle-protecting protein dystrophin than previous options.

On September 8, 2026, Novartis announced that the FDA accepted its Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) with Priority Review. This therapy is designed for patients whose mutations are amenable to exon 44 skipping, a group representing roughly 6% of the DMD population. This regulatory milestone follows a similar move by Dyne Therapeutics, whose BLA for z-rostudirsen (DYNE-251) was accepted in July. The FDA has set a target action date of January 21, 2027, for the Dyne therapy, which targets exon 51 skipping.

Recent clinical trials have shown next-generation therapies can achieve higher dystrophin levels than previous treatments.

The Dystrophin Differential

The anticipation surrounding these next-generation “exon-skipping” drugs stems from their ability to deliver much higher levels of dystrophin than the first wave of approved therapies. While the earliest versions of these drugs often produced dystrophin levels of approximately 1% of normal, Dyne’s z-rostudirsen demonstrated a mean absolute dystrophin expression of 8.72% in its DELIVER trial at the six-month mark. This muscle-content adjusted figure represents a substantial increase in potential potency.

Exon skipping works by allowing the body to “skip” over a missing or faulty section of the DMD gene, creating a shortened but functional version of the dystrophin protein. While this approach is mutation-specific—affecting about 13% of patients for exon 51 and 6% for exon 44—it remains a critical pathway for those who do not qualify for gene therapies like Elevidys. Gene therapies often have strict age limits or require patients to be ambulatory, leaving older or more advanced patients to rely on the “fortunate few” access currently found only in clinical trials.

Regulatory Deadlines and the 2027 Horizon

The community is currently navigating a period where advanced therapies are within reach but not yet broadly available. While trial participants are already seeing the effects of these high-potency drugs, the rest of the community must wait for the series of FDA decisions scheduled for early 2027. Following the January decision on Dyne’s z-rostudirsen, the focus will shift to established treatments undergoing their own transitions.

Sarepta Therapeutics is currently awaiting a decision on whether its existing therapies, Amondys 45 and Vyondys 53, will be converted from accelerated to traditional approval. The FDA is expected to issue a decision on these conversions by February 28, 2027, according to Sarepta Therapeutics. The conversion to traditional approval is often a key step in ensuring long-term insurance coverage and clinical confidence.

For families and advocates, such as those who gathered for World Duchenne Awareness Day, the arrival of drugs that can cross the 5% to 10% dystrophin threshold marks a turning point. The focus is no longer just on the presence of the protein, but on achieving the levels necessary to materially alter the course of the disease for those who have previously been “left behind” by the first wave of genomic medicine.

The post FDA to Decide on New Duchenne Muscular Dystrophy Therapies from Dyne and Novartis by Early 2027 appeared first on World Weekly News.